AZ 628
Tocris Bioscience, part of Bio-Techne | Catalog # 4836
Potent Raf kinase inhibitor
Product Description
AZ 628 is a potent, ATP-competitive inhibitor of Raf kinases (IC50 values are 29, 34 and 105 nM for c-Raf1, B-RafV600E and wild-type B-Raf, respectively). Displays selectivity for Raf kinases over a panel of 150 other kinases; inhibits activation of tyrosine protein kinases such as VEGFR2, Lyn, Flt1 and Fms. Also inhibits growth, and induces cell cycle arrest and apoptosis in colon and melanoma cell lines with the B-RafV600E mutation.Licensing Information
Sold with the permission of AstraZeneca UK Ltd.Product Specifications
Molecular Weight
451.52
Formula
C27H25N5O2
Storage
Store at +4°C
Purity
≥98% (HPLC)
Chemical Name
3-(1-Cyano-1-methylethyl)-N-[3-[(3,4-dihydro-3-methyl-4-oxo-6-quinazolinyl)amino]-4-methylphenyl]benzamide
CAS Number
878739-06-1
PubChem ID
11676786
InChI Key
ZGBGPEDJXCYQPH-UHFFFAOYSA-N
SMILES
CC(C)(C#N)C1=CC=CC(C(NC2=CC(NC3=CC(C(N(C)C=N4)=O)=C4C=C3)=C(C)C=C2)=O)=C1
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 45.15 | 100 |
Preparing Stock Solutions
for AZ 628
The following data is based on the product molecular weight 451.52
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.21 mL | 11.07 mL | 22.15 mL |
| 5 mM | 0.44 mL | 2.21 mL | 4.43 mL |
| 10 mM | 0.22 mL | 1.11 mL | 2.21 mL |
| 50 mM | 0.04 mL | 0.22 mL | 0.44 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Montagut Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008 PMID: 18559533
- Khazak Selective Raf inhibition in cancer therapy. Expert Opin.Ther.Targets 2007 PMID: 18020980
- Hatzivassiliou RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010 PMID: 20130576
Product Specific Notices for AZ 628
For research use only
Loading...
Loading...